VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis

Breast Cancer Research and Treatment

Volumn 85, Issue 2, 2004, Pages 161-171

  Wild, R ^a,b   Yokoyama, Y ^a   Dings, R P M ^a   Ramakrishnan, S ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Angiogenesis; Endostatin; Mammary carcinoma; Tumorigenesis; Vascular targeting; VEGF DT385 toxin

Indexed keywords

DIPHTHERIA TOXIN; RECOMBINANT VASCULOTROPIN; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR DIPHTHERIA TOXIN CONJUGATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; MOUSE; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; SOLID TUMOR; WEIGHT REDUCTION;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; DIPHTHERIA TOXIN; DISEASE MODELS, ANIMAL; ENDOSTATINS; FEMALE; HUMANS; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3342953026     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:BREA.0000025407.02896.ec     Document Type: Article

References (37)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971
2. Folkman J: The role of angiogenesis in tumor growth. Semin Cancer Biol 3: 65-71, 1992
3. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13: 9-22, 1999
4. Veikkola T, Alitalo K: VEGFs, receptors and angiogenesis. Semin Cancer Biol 9: 211-220, 1999
5. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med 77: 527-543, 1999
6. Dvorak HF, Sioussat TM, Brown LF, Berse B, Nagy JA, Sotrel A, Manseau EJ, Van de Water L, Senger DR: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 174: 1275-1278, 1991
7. Plate KH, Breier G, Millauer B, Ullrich A, Risau W: Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 53: 5822-5827, 1993
8. Plate KH, Risau W: Angiogenesis in malignant gliomas. Glia 15: 339-347, 1995
9. Arora N, Masood R, Zheng T, Cai J, Smith DL, Gill PS: Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 59: 183-188, 1999
10. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, Marks JW, Waltenberger J, Thorpe P, Rosenblum MG: In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci USA 99: 7866-7871. 2002
11. Ramakrishnan S, Olson TA, Bautch VL, Mohanraj D: Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56: 1324-1330, 1996
12. Wild R, Ramakrishnan S, Sedgewick J, Griffioen AW: Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res 59: 368-376, 2000
13. Olson TA, Mohanraj D, Roy S, Ramakrishnan S: Targeting the tumor vasculature: inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer 73: 865-870, 1997
14. Harris JR, Lippman ME, Veronesi U, Willett W: Breast cancer (2), N Engl J Med 327: 390-398, 1992
15. Amundadottir LT, Merlino G, Dickson RB: Transgenic mouse models of breast cancer. Breast Cancer Res Treat 39: 119-135, 1996
16. Maroulakou IG, Anver M, Garrett L, Green JE: Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc Natl Acad Sci USA 91: 11236-11240, 1994
17. Shibata MA, Jorcyk CL, Liu ML, Yoshidome K, Gold LG, Green JE: The C3(1)/SV40 T antigen transgenic mouse model of prostate and mammary cancer. Toxicol Pathol 26: 177-182, 1998
18. Ludlow JW: Interactions between SV40 large-tumor antigen and the growth suppressor proteins pRB and p53. FASEB J 7: 866-871, 1993
19. Yokoyama Y, Green JE, Sukhatme VP, Ramakrishnan S: Effect of endostatin on spontaneous tumorigenesis of mammary adenocarcinoma in a transgenic mouse model. Cancer Res 60: 4362-4365, 2000
20. Mohanraj D, Olson T, Ramakrishnan S: Expression of biologically active human vascular endothelial growth factor in yeast. Growth Factors 12: 17-27, 1995
21. Mohanraj D, Wahlsten JL, Ramakrishnan S: Expression and radiolabeling of recombinant proteins containing a phosphorylation motif. Protein Expr Purif 8: 175-182, 1996
22. Calvo A, Yokoyama Y, Smith LE, Ali I, Shih SC, Feldman AL, Libutti SK, Sundaram R, Green JE: Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int J Cancer 101: 224-234, 2002
23. Wild R, Dhanabal M, Olson TA, Ramakrishnan S: Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells. Br J Cancer 83: 1077-1083, 2000
24. Fogarty M: Learning from angiogenesis trial failures. Scientist 16: 33-35, 2002
25. Teicher BA, Emi Y, Kakeji Y, Northey D: TNP-470/minocycline/cytotoxic therapy: a systems approach to cancer therapy. Eur J Cancer 32A: 2461-2466, 1996
26. Teicher BA, Holden SA, Ara G, Sotomayor EA, Huang ZD, Chen YN, Brem H: Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 57: 920-925, 1994
27. Teicher BA, Sotomayor EA, Huang ZD: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52: 6702-6704, 1992
28. Dings RP, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH: The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res 63: 382-385, 2003
29. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997
30. Dhanabal M, Ramchandran R, Volk R, Stillman IE, Lombardo M, Iruela-Arispe ML, Simons M, Sukhatme VP: Endostatin: yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res 59: 189-197, 1999
31. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R, Min W: Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 17: 343-348, 1999
32. Yoon SS, Eto H, Lin CM, Nakamura H, Pawlik TM, Song SU, Tanabe KK: Mouse endostatin inhibits the formation of lung and liver metastases. Cancer Res 59: 6251-6256, 1999
33. Perletti G, Concari P, Giardini R, Marras E, Piccinini F, Folkman J, Chen L: Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 60: 1793-1796, 2000
34. Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390: 404-407, 1997
35. Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD: Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. Biochem Biophys Res Commun 268: 183-191, 2000
36. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D: Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284: 808-812, 1999
37. Calvo A, Feldman AL, Libutti SK, Green JE: Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice. Cancer Res 62: 3934-3938, 2002